RxDoctor Payments Data

Christian Wathen, MD

Internal Medicine · Mathews, VANPI 1457384232

Payments from drug & device makers

$1,881in general payments, 2019–2025

Across 123 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$340
  • Kowa Pharmaceuticals America, Inc.$178
  • Novo Nordisk$178
  • Lilly USA, LLC$168
  • Radius Health, Inc.$162
  • Amgen$157
  • plus $698 from 11 others

What the payments were for

  • Food & beverage$1,881100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,881 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$215,022
Medicare patients
430
Services billed
3,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$177,910
OzempicSemaglutide124$147,867
TrulicityDulaglutide133$135,879
MounjaroTirzepatide64$72,213
FarxigaDapagliflozin Propanediol44$47,101
XareltoRivaroxaban43$43,053
MyrbetriqMirabegron52$32,220
Synjardy XrEmpagliflozin/Metformin Hcl29$26,293
JardianceEmpagliflozin26$22,658
Janumet XrSitagliptin Phos/Metformin Hcl21$20,011
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,765
Breo ElliptaFluticasone/Vilanterol34$16,272
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,106
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$10,198
Repatha SureclickEvolocumab16$9,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$168$208,093197 claims
PfizerEliquis$88$177,910197 claims
Novo NordiskOzempic$178$147,867124 claims
AstraZenecaFarxiga, Breztri Aerosphere$340$58,20861 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$18$43,23568 claims
Johnson & JohnsonXarelto$113$43,05343 claims
Astellas Pharma US IncMyrbetriq$45$32,22052 claims
AbbVieSynthroid$152$3,05575 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Mathews

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →